Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta

Heart and Vessels

Volumn 28, Issue 2, 2013, Pages 246-254

  Lunder, Mojca ^a   Žiberna, Lovro ^a   Janić, Miodrag ^a   Jerin, Aleš ^a   Skitek, Milan ^a   Šabovič, Mišo ^a   Drevenšek, Gorazd ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Atorvastatin; Chronic low dose treatment; Endothelium dependent relaxation; Ischemia reperfusion injury; Losartan

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LOSARTAN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERY ENDOTHELIUM; ARTICLE; BLOOD FLOW VELOCITY; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART PROTECTION; IN VITRO STUDY; ISOLATED ARTERY; ISOLATED HEART; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; REPERFUSION INJURY; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; TREATMENT DURATION; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; BIOLOGICAL MARKERS; BLOOD PRESSURE; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEART; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOSARTAN; MALE; MYOCARDIAL REPERFUSION INJURY; PERFUSION; PYRROLES; RATS; RATS, WISTAR; TIME FACTORS; VASODILATION; VASODILATOR AGENTS;

EID: 84880573487     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-012-0259-0     Document Type: Article

References (51)

1. Fuster V, Kelly BB, Vedanthan R (2011) Global cardiovascular health: urgent need for an intersectoral approach. J Am Coll Cardiol 58:1208-1210
2. Mihos CG, Salas MJ, Santana O (2010) The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev 18:298-304
3. Sadowitz B, Seymour K, Costanza MJ, Gahtan V (2010) Statin therapy - part II: clinical considerations for cardiovascular disease. Vasc Endovascular Surg 44:421-433
4. Tran HA, Schwartzbard A, Weintraub HS (2011) Role of RAAS inhibition in the prevention of cardiovascular disease. Curr Treat Options Cardiovasc Med 13:279-288
5. Reriani MK, Dunlay SM, Gupta B, West CP, Rihal CS, Lerman LO, Lerman A (2011) Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil 18:704-716
6. Suh JW, Choi DJ, Chang HJ, Cho YS, Youn TJ, Chae IH, Kim KI, Kim CH, Kim HS, Oh BH, Park YB (2010) HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J Korean Med Sci 25:16-23
7. Nagashima H, Endo M (2011) Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Heart Vessels 26:428-434
8. Skogastierna C, Luksha L, Kublickiene K, Eliasson E, Rane A, Ekstrom L (2011) Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide. Heart Vessels 26:628-636
9. Horiuchi Y, Hirayama S, Soda S, Seino U, Kon M, Ueno T, Idei M, Hanyu O, Tsuda T, Ohmura H, Miida T (2010) Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. J Atheroscler Thromb 17:722-729
10. Ghaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP (2010) Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology 18:169-177
11. Sugiyama M, Ohashi M, Takase H, Sato K, Ueda R, Dohi Y (2005) Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels 20:133-136
12. Lee KJ, Moon JY, Choi HK, Kim HO, Hur GY, Jung KH, Lee SY, Kim JH, Shin C, Shim JJ, In KH, Yoo SH, Kang KH (2010) Immune regulatory effects of simvastatin on regulatory T cell-mediated tumour immune tolerance. Clin Exp Immunol 161:298-305
13. Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, Rahsepar AA, Amini M, Sahebkar A, Mohammadi M, Ferns GA (2011) Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids 46:333-340
14. Abela GS, Vedre A, Janoudi A, Huang R, Durga S, Tamhane U (2011) Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization. Am J Cardiol 107:1710-1717
15. Hamada M, Sugimoto M, Matsui H, Mizuno T, Shida Y, Doi M, Fukushima H, Nishio K, Yoshioka A, Shima M (2011) Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions. Thromb Haemost 105:313-320
16. Nemati F, Rahbar-Roshandel N, Hosseini F, Mahmoudian M, Shafiei M (2011) Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension. Clin Exp Hypertens 33:66-76
17. Honjo T, Yamaoka-Tojo M, Inoue N (2011) Pleiotropic effects of ARB in vascular metabolism - focusing on atherosclerosis-based cardiovascular disease. Curr Vasc Pharmacol 9:145-152
18. Yokota T, Osanai T, Hanada K, Kushibiki M, Abe N, Oikawa K, Tomita H, Higuma T, Yokoyama J, Hanada H, Okumura K (2010) Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. Heart Vessels 25:460-468
19. Chen HQ, Tan HY, Yang YW, Qiu L, Liu XQ (2010) Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome. Heart Vessels 25:77-81
20. Miyoshi T, Doi M, Hirohata S, Kamikawa S, Usui S, Ogawa H, Sakane K, Izumi R, Ninomiya Y, Kusachi S (2011) Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients. Heart Vessels 26:408-413
21. Fujita H, Sakamoto T, Komatsu K, Fujishima H, Morii T, Narita T, Takahashi T, Yamada Y (2011) Reduction of circulating superoxide dismutase activity in type 2 diabetic patients with microalbuminuria and its modulation by telmisartan therapy. Hypertens Res 34:1302-1308
22. Landmesser U, Drexler H (2006) Effect of angiotensin II type 1 receptor antagonism on endothelial function: role of bradykinin and nitric oxide. J Hypertens Suppl 24:S39-S43
23. Barrios V, Escobar C, Calderon A, Barrios S, Navarro-Cid J, Ferrer E, Echarri R (2010) Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study. Heart Vessels 25:51-56
24. Hussein O, Shneider J, Rosenblat M, Aviram M (2002) Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 40:28-34
25. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M (2003) Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 107:106-112
26. Liu L, Zhao SP, Zhou HN, Li QZ, Li JX (2007) Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension. J Cardiovasc Pharmacol 50:50-55
27. Koh KK, Han SH, Oh PC, Shin EK, Quon MJ (2010) Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis 209:307-313
28. Lunder M, Janic M, Habjan S, Sabovic M (2011) Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males - a pilot study. Atherosclerosis 215:446-451
29. Lunder M, Janic M, Sabovic M (2011) Reduction of age-associated arterial wall changes by low-dose valsartan. Eur J Cardiovasc Prev Rehabil. doi: 10.1177/1741826711423104
30. Lunder M, Janic M, Jug B, Sabovic M (2011) The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial. Eur J Intern Med. doi: 10.1016/j.ejim.2011.11.011
31. Kuhar P, Lunder M, Drevensek G (2007) The role of gender and sex hormones in ischemic-reperfusion injury in isolated rat hearts. Eur J Pharmacol 561:151-159
32. Ziberna L, Lunder M, Tramer F, Drevensek G, Passamonti S (2011) The endothelial plasma membrane transporter bilitranslocase mediates rat aortic vasodilation induced by anthocyanins. Nutr Metab Cardiovasc Dis. doi: 10.1016/j.numecd.2011.02.005
33. Ziberna L, Zorman T, Drevensek G (2009) Characterization of histamine-induced relaxation in pre-contracted rat aorta. Inflamm Res 58(Suppl 1):63-65
34. Hirota T, Nonaka A, Matsushita A, Uchida N, Ohki K, Asakura M, Kitakaze M (2011) Milk casein-derived tripeptides, VPP and IPP induced NO production in cultured endothelial cells and endothelium-dependent relaxation of isolated aortic rings. Heart Vessels 26:549-556
35. Garcia-Villalon AL, Amezquita YM, Monge L, Fernandez N, Climent B, Sanchez A, Dieguez G (2005) Effect of ischemia duration and nitric oxide on coronary vasoconstriction after ischemia-reperfusion. Eur J Pharmacol 509:165-170
36. Flynn JD, Akers WS (2003) Effects of the angiotensin II subtype 1 receptor antagonist losartan on functional recovery of isolated rat hearts undergoing global myocardial ischemia-reperfusion. Pharmacotherapy 23:1401-1410
37. Xu HC, Qian LB, Ru XC, Miao HF, Ye ZG, Wang HP (2010) Electrophysiological effect of atorvastatin on isolated rat hearts injured by ischemia/reperfusion. Zhejiang Da Xue Xue Bao Yi Xue Ban 39:589-593
38. Spurney CF, Sali A, Guerron AD, Iantorno M, Yu Q, Gordish-Dressman H, Rayavarapu S, van der Meulen J, Hoffman EP, Nagaraju K (2011) Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice. J Cardiovasc Pharmacol Ther 16:87-95
39. Schmechel A, Grimm M, El-Armouche A, Hoppner G, Schwoerer AP, Ehmke H, Eschenhagen T (2009) Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovasc Res 82:100-106
40. Filusch A, Buss S, Hardt S, Katus HA, Kuecherer HF, Hansen A (2008) Evaluation cardioprotective effects of atorvastatin in rats by real time myocardial contrast echocardiography. Echocardiography 25:974-981
41. Li D, Xia K, Li NS, Luo D, Wang S, Jiang DJ, Deng HW, Li YJ (2007) Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. Can J Physiol Pharmacol 85:783-789
42. Garjani A, Andalib S, Biabani S, Soraya H, Doustar Y, Maleki-Dizaji N (2011) Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat. Eur J Pharmacol 666:135-141
43. Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, Hughes MG, McAdoo DJ, Uretsky BF, Birnbaum Y (2007) The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 21:321-330
44. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, Uretsky BF, Birnbaum Y (2006) Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. Cardiovasc Drugs Ther 20:27-36
45. Sonmez Uydes-Dogan B, Topal G, Takir S, Ilkay Alp F, Kaleli D, Ozdemir O (2005) Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings. Life Sci 76:1771-1786
46. + channels in mesenteric artery from type 2 diabetic GK rat. J Pharmacol Sci 112:299-309
47. Torrens C, Kelsall CJ, Hopkins LA, Anthony FW, Curzen NP, Hanson MA (2009) Atorvastatin restores endothelial function in offspring of protein-restricted rats in a cholesterol-independent manner. Hypertension 53:661-667
48. Yu XL, Zhang HJ, Ren SD, Geng J, Wu TT, Chen WQ, Ji XP, Zhong L, Ge ZM (2011) Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury. Coron Artery Dis 22:87-91
49. Amin KA, Abd El-Twab TM (2009) Oxidative markers, nitric oxide and homocysteine alteration in hypercholesterolemic rats: role of atorvastatin and cinnamon. Int J Clin Exp Med 2:254-265
50. Huisamen B, Perel SJ, Friedrich SO, Salie R, Strijdom H, Lochner A (2011) ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. Mol Cell Biochem 349:21-31
51. Mensah K, Mocanu MM, Yellon DM (2005) Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol 45:1287-1291